Professional Roles and Career Progression
Michael J. LaBarre has held senior leadership positions at Halozyme Therapeutics, Inc., a San Diego-based biopharmaceutical company focused on oncology and drug delivery therapies. He served as Senior Vice President and Chief Technical Officer (CTO) from June 2008 until his retirement effective March 17, 2025. Prior to his CTO role, he joined Halozyme as Vice President of Product Development.
In August 2015, Michael LaBarre was appointed Chief Scientific Officer (CSO) at Halozyme, expanding his responsibilities beyond technical oversight to include research and development of early pipeline assets. Throughout his tenure, he was a key driver in advancing the company’s proprietary technologies, notably the ENHANZE® drug delivery platform, which facilitates subcutaneous delivery of high-dose/volume biologics.
Expertise and Technical Foundation
Dr. LaBarre holds a Ph.D. in Chemistry from the University of Arizona, providing a strong scientific foundation in protein chemistry and FDA regulatory standards. His career spans over 25 years in biopharmaceutical research and drug development, with extensive experience in:
- Biotech drug discovery and development
- Regulatory compliance and clinical development
- Strategic partnerships within regulated pharmaceutical ecosystems
- Advancing subcutaneous biologic drug delivery technologies
He contributed significantly to the development and commercialization of Halozyme’s novel oncology therapies and drug-delivery solutions, underscoring his technical leadership within the company.
Contributions and Public Engagements
Michael LaBarre has been publicly associated with Halozyme’s positive clinical advancements, including presentations on the successful clinical study data demonstrating rapid subcutaneous administration of 10 mL biologic products using Halozyme's ENHANZE® technology. He also co-authored peer-reviewed publications related to recombinant human hyaluronidase PH20 (rHuPH20), a key component of ENHANZE®, which is pivotal in enhancing subcutaneous drug delivery.
Insider Transactions and Shareholding
Up to early 2025, Michael LaBarre was actively involved in insider share transactions at Halozyme. Over the past year leading to his retirement, he sold approximately 191,697 shares, including a significant trade of 21,697 shares in late February 2025 valued at around $1.26 million. These sales reflect his shareholder activity coinciding with the period leading to his retirement announcement.
Education and Additional Credentials
- Ph.D. in Chemistry – University of Arizona
- Background in biopharmaceutical research aligned with regulatory frameworks under FDA
- Reported J.D. from Boston College Law School (noted in SEC filings), indicating a legal educational background supplementing his technical expertise
Company Context and Leadership Transition
Michael LaBarre’s retirement as Senior Vice President and Chief Technical Officer represents a key leadership transition at Halozyme as of March 2025. His extended tenure and broad responsibility underscore his significant role in shaping Halozyme’s strategic direction in drug development and product innovation during a dynamic period of the company’s growth.
This profile highlights Michael LaBarre's deep technical expertise, leadership in innovative drug delivery systems, considerable industry experience, and his impactful role at Halozyme Therapeutics until early 2025. These insights provide a comprehensive understanding of his professional background, technical competencies, and influential contributions to Halozyme’s biopharmaceutical development efforts.
